Alnylam Pharmaceuticals forward PE ALNY
Share price divided by analysts' consensus earnings for the next twelve months, since 2025.
- Today, Nov 3, 2026
- 18.9×
- Peer median
- 33.8×
Alnylam Pharmaceuticals' forward PE is 18.9× as of Nov 3, 2026.
The median for 10 biotech stocks of a similar size is 33.8×.
Forward PE over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 18.8× | 18.8× | 74.0× |
| 2025 | 74.1× | 73.5× | 163× |
Against its peers
Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first, today.
| Company | Forward PE |
|---|---|
| ALNYAlnylam Pharmaceuticals | 18.9× |
| INCYIncyte | 51.3× |
| UTHRUnited Therapeutics | 22.6× |
| EXELExelixis | n/m |
| NBIXNeurocrine Biosciences | n/m |
| HALOHalozyme Therapeutics | n/m |
| TECHBIO-TECHNE | n/m |
| ONCBeOne Medicines | 45.0× |
| RGENRepligen | n/m |
| KRYSKrystal Biotech | n/m |
| REGNRegeneron Pharmaceuticals | 15.1× |
| Peer median | 33.8× |
Where Alnylam Pharmaceuticals ranks
What the forward PE tells you
Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.
Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.
More on Alnylam Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.